权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Phase IIB Plasticity-based Adaptive Cognitive Remediation for Alzheimers Disease

IIB 期基于可塑性的阿尔茨海默病自适应认知疗法

基本信息

批准号：
10603717
负责人：
Hyun Kyu Lee
金额：
$ 92.49万
依托单位：
POSIT SCIENCE CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-30 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10603717
关键词：
Adult Age Age-associated memory impairment Alzheimer disease prevention Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk American Assessment tool Brain Chronology Cognition Cognitive Cognitive remediation Collaborations Conduct Clinical Trials Dementia Development Devices Economic Burden Effectiveness Elderly Enrollment Epidemiology Evaluation Follow-Up Studies Functional Magnetic Resonance Imaging Goals Home Hour Impaired cognition Individual Internet Interval training Iowa Longevity Maintenance Measures Mediating Modeling Monitor Nerve Degeneration Nervous System Physiology Neuronal Plasticity Outcome Participant Pathology Performance Pharmacotherapy Phase Phase II Clinical Trials Play Population Prevention Randomized Schedule Source Standardization Structure Testing Texas Therapeutic Time Training Training Programs Universities active control age effect blood-based biomarker brain health brain volume cognitive ability cognitive function cognitive performance cognitive rehabilitation cognitive testing cognitive training commercialization comparative efficacy computerized design efficacy evaluation evidence base follow up assessment follow-up improved information processing neurobehavioral novel phase I trial phase II trial processing speed programs recruit resilience social study population tool white matter

项目摘要

Project Summary Abstract The primary objectives of the current project are 1) to evaluate the longer-term efficacy of PACR-AD cognitive training (PACR-CT) measured 5 years after the completion of initial 10 weeks of training, 2) to determine the efficacy of the 10 weeks of booster training after 5 years from the initial training completion, and 3) to redesign the PACR-CT for optimal training schedule to sustain and potentially further-grow program-delivered benefits. We will examine prolonged PACR-CT efficacy compared to Active Control (Casual Games) at 5 years after training by comparing 1) cognitive and functional performance, 2) structural (white matter integrity and brain volume) and functional brain changes (rsfMRI and task-fMRI) and 3) neurodegeneration assessed with blood- based biomarkers (pTau-181) predictive of AD risk. Next, we will examine the general booster efficacy (pre- vs. post-booster training), and the interaction between initial training and booster training by comparing the change scores between groups. Finally, we will modify PACR-CT schedule with the optimal booster training interval calculated based on the rate of natural cognitive decline measured from Aim 1 and the performance improvement from the 10 weeks of booster training from Aim 2. Evaluation of the longer-term effect PACR-CT and the booster effect will be used to obtain FDA clearance for the program and commercialize it as the evidence-based prevention device indicated for age-related cognitive decline. This project should result in the development of a new, and powerful tool to provide effective adjunctive therapy that results in far greater resilience against cognitive impairment in a substantially greater pre-AD population.

项目摘要